

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Caplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Caplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

NEWS 35 JAN 28 MEDLINE and LMedLINE reloaded with enhancements  
NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:42:36 ON 13 FEB 2008

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:42:51 ON 13 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 FEB 2008 HIGHEST RN 1003006-87-8  
DICTIONARY FILE UPDATES: 12 FEB 2008 HIGHEST RN 1003006-87-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> E "DMXAA"/CN 25

E1	1	DMX 400YB40RBK/CN
E2	1	DMX 7R/CN
E3	1 -->	DMXAA/CN
E4	1	DMXAA SODIUM SALT/CN
E5	1	DMXAA-DICLOFENAC MIXTURE/CN
E6	1	DMXB-A/CN
E7	1	DMY PROTEIN (ORYZIAS CURVINOTUS GENE DMY)/CN

E8 1 DMZ/CN  
 E9 3 DN/CN  
 E10 1 DN (DISPERSANT)/CN  
 E11 1 DN (HUMAN PAPILLOMAVIRUS 35 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN  
 E12 1 DN (HUMAN PAPILLOMAVIRUS 39 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN  
 E13 1 DN (HUMAN PAPILLOMAVIRUS 44 GENE L1 244-NUCLEOTIDE FRAGMENT)/CN  
 E14 1 DN (HUMAN PAPILLOMAVIRUS 45 GENE L1 256-NUCLEOTIDE FRAGMENT)/CN  
 E15 1 DN (HUMAN PAPILLOMAVIRUS 51 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN  
 E16 1 DN (HUMAN PAPILLOMAVIRUS 56 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN  
 E17 1 DN (HUMAN PAPILLOMAVIRUS 59 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN  
 E18 1 DN (HUMAN PAPILLOMAVIRUS 66 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN  
 E19 1 DN (HUMAN PAPILLOMAVIRUS 68 GENE L1 120-NUCLEOTIDE FRAGMENT)/CN  
 E20 1 DN (HUMAN PROTEIN SERINE/THREONINE KINASE (PHOSPHORYLATING) GENE  
 PLUS FLANKS)/CN  
 E21 1 DN (PESTICIDE)/CN  
 E22 2 DN 003/CN  
 E23 1 DN 0081/CN  
 E24 1 DN 02/CN  
 E25 1 DN 099/CN

=> S E3

L1 1 DMXAA/CN

=> DIS L1 1 SQIDE

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 117570-53-3 REGISTRY

CN 9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo- (CA INDEX NAME)

OTHER NAMES:

CN 5,6-Dimethylxanthenone-4-acetic acid

CN AS 1404

CN DMXAA

CN NSC 640488

MF C17 H14 O4

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CIN, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS\*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

(\*File contains numerically searchable property data)


DT.CA CAplus document type: Conference; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

170 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 172 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> E "DMXAA"/CN 25
E1      1      DMX 400YB40RBK/CN
E2      1      DMX 7R/CN
E3      1  --> DMXAA/CN
E4      1      DMXAA SODIUM SALT/CN
E5      1      DMXAA-DICLOFENAC MIXTURE/CN
E6      1      DMXB-A/CN
E7      1      DMY PROTEIN (ORYZIAS CURVINOTUS GENE DMY)/CN
E8      1      DMZ/CN
E9      3      DN/CN
E10     1      DN (DISPERSANT)/CN
E11     1      DN (HUMAN PAPILLOMAVIRUS 35 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E12     1      DN (HUMAN PAPILLOMAVIRUS 39 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E13     1      DN (HUMAN PAPILLOMAVIRUS 44 GENE L1 244-NUCLEOTIDE FRAGMENT)/CN
E14     1      DN (HUMAN PAPILLOMAVIRUS 45 GENE L1 256-NUCLEOTIDE FRAGMENT)/CN
E15     1      DN (HUMAN PAPILLOMAVIRUS 51 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
E16     1      DN (HUMAN PAPILLOMAVIRUS 56 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
E17     1      DN (HUMAN PAPILLOMAVIRUS 59 GENE L1 253-NUCLEOTIDE FRAGMENT)/CN
E18     1      DN (HUMAN PAPILLOMAVIRUS 66 GENE L1 250-NUCLEOTIDE FRAGMENT)/CN
E19     1      DN (HUMAN PAPILLOMAVIRUS 68 GENE L1 120-NUCLEOTIDE FRAGMENT)/CN
E20     1      DN (HUMAN PROTEIN SERINE/THREONINE KINASE (PHOSPHORYLATING) GENE
PLUS FLANKS)/CN
E21     1      DN (PESTICIDE)/CN
E22     2      DN 003/CN
E23     1      DN 0081/CN
E24     1      DN 02/CN
E25     1      DN 099/CN

=> E "GEMCITABINE"/CN 25
E1      1      GEMCADIOL/CN
E2      1      GEMCAT 200/CN
E3      1  --> GEMCITABINE/CN
E4      1      GEMCITABINE 5'-DIPHOSPHATE/CN
E5      1      GEMCITABINE HYDROCHLORIDE/CN
E6      1      GEMCITABINE TRIPHOSPHATE/CN
E7      1      GEMEDINE/CN
E8      1      GEMEDIS/CN
E9      1      GEMEPROST/CN
E10     1      GEMETREL/CN
E11     1      GEMEX/CN
E12     1      GEMEX AGENT 03/CN
E13     1      GEMFIBROZIL/CN
E14     1      GEMFIBROZIL 1-O-B-D-GLUCURONIDE/CN
```

E15 1 GEMFIBROZIL GLUCURONIDE/CN  
 E16 1 GEMFIBROZIL POTASSIUM SALT/CN  
 E17 1 GEMFIBROZIL SODIUM SALT/CN  
 E18 1 GEMFIBROZIL-VITAMIN B6 MIXTURE/CN  
 E19 1 GEMFLEX 1031C/CN  
 E20 1 GEMFLEX 307/CN  
 E21 1 GEMFLEX 409/CN  
 E22 1 GEMGEL 100/CN  
 E23 1 GEMGEL 100+/CN  
 E24 1 GEMICALCONE A/CN  
 E25 1 GEMICALCONE B/CN

=> S E3

L2 1 GEMCITABINE/CN

=> DIS L2 1 SQIDE

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

RN 95058-81-4 REGISTRY

CN Cytidine, 2'-deoxy-2',2'-difluoro- (CA INDEX NAME)

OTHER NAMES:

CN 2',2'-Difluoro-2'-deoxycytidine

CN 2',2'-Difluorodeoxycytidine

CN 2'-Deoxy-2',2'-difluorocytidine

CN DDFC

CN DfCd

CN DfCdCyd

CN Folfugem

CN Gemcitabine

CN Gemcitabine

CN LY 188011

CN NSC 613327

FS STEREOSEARCH

MF C9 H11 F2 N3 O4

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DRUGU, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)

Other Sources: WHO

DT.CA CAPLUS document type: Book; Conference; Dissertation; Journal; Patent


RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); USES (Uses)

Absolute stereochemistry. Rotation (+).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3731 REFERENCES IN FILE CA (1907 TO DATE)  
 73 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 3772 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus medline wpids uspatfull  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
15.22	15.43

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 15:43:57 ON 13 FEB 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:43:57 ON 13 FEB 2008

FILE 'WPIDS' ENTERED AT 15:43:57 ON 13 FEB 2008  
 COPYRIGHT (C) 2008 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 15:43:57 ON 13 FEB 2008  
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 and l2  
 L3 7 L1 AND L2

=> d l3 1-7 ibib, abs

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:984120 CAPLUS

DOCUMENT NUMBER: 143:279360

TITLE: Methods of detecting CD133 antigen (AC133) expression level and use as biomarker for human cancer diagnosis and therapy monitor

INVENTOR(S): Penning, Maarten Tjerk; Van den Broek, Sebastiaan Johannes Jacobus; Voest, Emile Eugene; Beerepoot, Laurens Victor; Mehra, Niven

PATENT ASSIGNEE(S): Primagen Holding B. V., Neth.; UMC Utrecht Holding B. V.

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2005083123 A1 20050909 WO 2005-NL155 20050302  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1571225 A1 20050907 EP 2004-75686 20040302  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK  
 CA 2558604 A1 20050909 CA 2005-2558604 20050302  
 EP 1725679 A1 20061129 EP 2005-710924 20050302  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR  
 US 2007077578 A1 20070405 US 2006-514345 20060831  
 PRIORITY APPLN. INFO.: EP 2004-75686 A 20040302  
 US 2004-549450P P 20040302  
 EP 2005-710924 A 20050302  
 WO 2005-NL155 W 20050302  
 AB This invention provides methods of detecting CD133 antigen (AC133) expression level and use as a biomarker for human cancer diagnosis and therapy monitor. Blood anal. including number of circulating endothelial cells and expression levels of human genes AC133 (CD133), EST032 and U1A evaluated by NASBA anal., were determined prior to and during chemotherapy using drugs such as angiostatin or PrimMed01, gemcitabine, and cisplatin, for a wide range of human tumor types. A use of a nucleic acid mol. comprising at least part of a sequence of AC133 or an analog thereof for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid mol.  
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:975665 CAPLUS  
 DOCUMENT NUMBER: 143:264929  
 TITLE: Methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases  
 INVENTOR(S): Penning, Maarten Tjerk; Beerepoot, Laurens Victor; Van Den Broek, Sebastiaan Johannes Jacobus; Mehra, Niven; Voest, Emile Eugene  
 PATENT ASSIGNEE(S): Primagen Holding B.V., Neth.; UMC Utrecht Holding B.V.  
 SOURCE: Eur. Pat. Appl., 28 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1571225	A1	20050907	EP 2004-75686	20040302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CA 2558604	A1	20050909	CA 2005-2558604	20050302
WO 2005083123	A1	20050909	WO 2005-NL155	20050302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NJ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1725679 A1 20061129 EP 2005-710924 20050302

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: EP 2004-75686 A 20040302  
 US 2004-549450P P 20040302  
 WO 2005-NL155 W 20050302

AB The invention provides methods for detecting AC133 antigen mRNA for diagnosis and treatment of cancer and other diseases. AC133 antigen mRNA may be quantitated by PCR, RT-PCR, NASBA, SDA, TMA, bDNA or rolling circle amplification. Diseases include cancer and heart disease, high blood pressure, ischemia, stroke, psoriasis, Crohn's disease, rheumatoid arthritis, endometriosis, atherosclerosis, obesity, diabetes mellitus, diabetic retinopathy, macular degeneration, Alzheimer's disease, Peutz Jegher's syndrome, multiple sclerosis, systemic lupus erythematosus, Wegener's granulomatosis, vasculitis, sickle cell disease, thalassemia and angina.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:202462 CAPLUS

DOCUMENT NUMBER: 138:226761

TITLE: Synergistic anticancer combinations containing 5,6-dimethylxanthene-4-acetic acid

INVENTOR(S): Wilson, William Robert; Siim, Bronwyn Gae

PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020259	A2	20030313	WO 2002-GB4025	20020903
WO 2003020259	A3	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2458459	A1	20030313	CA 2002-2458459	20020903
AU 2002324143	A1	20030318	AU 2002-324143	20020903
AU 2002324143	B2	20070913		
EP 1423105	A2	20040602	EP 2002-758562	20020903
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			



IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002012258	A	20041019	BR 2002-12258	20020903
JP 2005509599	T	20050414	JP 2003-524567	20020903
CN 1708296	A	20051214	CN 2002-817257	20020903
NZ 531045	A	20060831	NZ 2002-531045	20020903
EP 1759694	A2	20070307	EP 2006-77049	20020903

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,  
LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI

NZ 546573	A	20070531	NZ 2002-546573	20020903
CN 1994287	A	20070711	CN 2006-10151393	20020903
NO 2004000591	A	20040430	NO 2004-591	20040210
ZA 2004001078	A	20050415	ZA 2004-1078	20040210
US 2004204480	A1	20041014	US 2004-790943	20040302
MX 2004PA02004	A	20050217	MX 2004-PA2004	20040302
IN 2004CN00684	A	20060113	IN 2004-CN684	20040402
US 2007060637	A1	20070315	US 2006-592678	20061103
AU 2007202083	A1	20070531	AU 2007-202083	20070509

PRIORITY APPLN. INFO.:

			GB 2001-21285	A	20010903
			AU 2002-324143	A3	20020903
			CN 2002-817257	A3	20020903
			EP 2002-758562	A3	20020903
			WO 2002-GB4025	W	20020903
			US 2004-790943	A1	20040302

AB The present invention relates to synergistic combinations of the 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compds., Vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have antitumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compds. containing the combinations. The antitumor activity and host toxicity of DMXAA/cytotoxic drug combinations was assessed by varying the dose of chemotherapeutic drug up to the toxicity limit, with co-administration of a fixed DMXAA dose (80 µmol/kg, ca. 80% of MTD), and evaluating subsequent tumor growth delay. Of the 7 drugs investigated, 4 (doxorubicin, 5-fluorouracil, cyclophosphamide and cisplatin) had appreciable activity against this tumor as indicated by dose-response relationships providing significant slopes by linear regression, and highly significant growth delays of 10 days at their MTDs.

L3 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2007:221355 USPATFULL

TITLE: Method For Producing Fiber Composite Semi-Finished Products By Means Of A Round Braiding Technique

INVENTOR(S): Gessler, Andreas, Haar, GERMANY, FEDERAL REPUBLIC OF  
Maidl, Franz, Wallerfing, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): EADS DEUTSCHLAND GMBH, Ottobrunn, GERMANY, FEDERAL  
REPUBLIC OF, 85521 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007193439	A1	20070823
APPLICATION INFO.:	US 2005-592678	A1	20050406 (10)
	WO 2005-DE603		20050406
			20060913 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2004-10200401731120040406	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O.	

BOX 14300, WASHINGTON, DC, 20044-4300, US  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 289

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Method of producing fiber composite semifinished products by means of a circular braiding technique, a braiding core being braided with braiding threads which are unwound by means of bobbins circling concentrically about the braiding core in different directions, characterized in that the bobbins of one circling direction are fitted with reinforcing threads and the bobbins of the opposite circling direction are at least partially fitted with supporting threads, the supporting threads at least partially consisting of thermoplastic threads.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2007:89005 USPATFULL  
TITLE: Diagnosis of (a risk of ) disease and monitoring of therapy

INVENTOR(S): Penning, Maarten Tjerk, Utrecht, NETHERLANDS  
van den Broek, Sebastiaan Johannes Jacobus,  
Heerhugowaard, NETHERLANDS  
Voest, Emile Eugene, Soest, NETHERLANDS  
Beerepoot, Laurens Victor, Utrecht, NETHERLANDS  
Mehra, Niven, Utrecht, NETHERLANDS

PATENT ASSIGNEE(S): PrimaGen Holding B.V., Amsterdam, NETHERLANDS (non-U.S. corporation)  
UMC Utrecht Holding B.V., Utrecht, NETHERLANDS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007077578	A1	20070405
APPLICATION INFO.:	US 2006-514345	A1	20060831 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2005-NL155, filed on 2 Mar 2005, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2004-5710924	20040302
	US 2004-549450P	20040302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TRASK BRITT, P.O. BOX 2550, SALT LAKE CITY, UT, 84110, US	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	1272	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method for typing a sample of an individual suffering from, or at risk of suffering from, a disease and a method for monitoring treatment of an individual suffering from a disease comprising determining whether a sample from the individual comprises an expression product of AC133 in an amount that is indicative for the disease or for the treatment thereof. That amount is preferably quantified and compared with a reference value. In one aspect, the amount is compared with an amount of the expression product present in a sample that was obtained from the individual before treatment. Use of a nucleic acid molecule comprising at least part of a sequence of AC133,

or an analogue thereof, for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2007:69382 USPATFULL  
TITLE: Anti-cancer combinations  
INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND  
Siim, Bronwyn G., Mt. Eden, NEW ZEALAND  
PATENT ASSIGNEE(S): Cancer Research Technology Limited (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007060637	A1	20070315
APPLICATION INFO.:	US 2006-592678	A1	20061103 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1277	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6 -dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2004:261978 USPATFULL  
TITLE: Anti-cancer combinations  
INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND  
Siim, Bronwyn G., Mt. Eden, NEW ZEALAND  
PATENT ASSIGNEE(S): Cancer Research Technology Limited (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004204480	A1	20041014
APPLICATION INFO.:	US 2004-790943	A1	20040302 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1297	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:42:36 ON 13 FEB 2008)

FILE 'REGISTRY' ENTERED AT 15:42:51 ON 13 FEB 2008

	E "DMXAA"/CN 25
L1	1 S E3
	E "DMXAA"/CN 25
	E "GEMCITABINE"/CN 25
L2	1 S E3

FILE 'CAPLUS, MEDLINE, WPIDS, USPATFULL' ENTERED AT 15:43:57 ON 13 FEB 2008

L3 7 S L1 AND L2

=> s l1 and antimetabolite

L4 4 L1 AND ANTIMETABOLITE

=> d l4 1-4 ibib, abs

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:284727 CAPLUS

DOCUMENT NUMBER: 142:85467

TITLE: The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies

AUTHOR(S): Newell, D. R.; Silvester, J.; McDowell, C.; Burtles, S. S.

CORPORATE SOURCE: Cancer Research UK, Drug Development Office, London, WC2A 3PX, UK

SOURCE: European Journal of Cancer (2004), 40(6), 899-906

PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Pre-clin. toxicol. studies in rodents and Phase I clin. trial data are summarized for 14 novel anticancer therapies. With only one exception, an antifolate antimetabolite, rodent toxicol. predicted a safe Phase I trial starting dose and the majority of the dose limiting toxicities, in particular haematol. toxicity. For targeted agents with well-defined pharmacodynamic markers, illustrated in the current study by 3 anti-endocrine drugs and one resistance modifier, the definition of a maximum tolerated dose can be avoided. Together with earlier data, the current study confirms that pre-clin. toxicol. studies in a non-rodent species are not routinely needed for the safe conduct of early clin. trials with new cancer chemotherapies.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2007:69382 USPATFULL  
TITLE: Anti-cancer combinations  
INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND  
Siim, Bronwyn G., Mt. Eden, NEW ZEALAND  
PATENT ASSIGNEE(S): Cancer Research Technology Limited (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007060637	A1	20070315
APPLICATION INFO:	US 2006-592678	A1	20061103 (11)
RELATED APPLN. INFO:	Continuation of Ser. No. US 2004-790943, filed on 2 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199, US	

NUMBER OF CLAIMS: 23  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 2 Drawing Page(s)  
LINE COUNT: 1277  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2005:240102 USPATFULL  
TITLE: Hydrogels used to deliver medicaments to the eye for  
the treatment of posterior segment diseases  
INVENTOR(S): Schultz, Clyde L., Ponte Vedra, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005208102	A1	20050922
APPLICATION INFO.:	US 2004-821718	A1	20040409 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-461354P	20030409 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINCH IP LLC, P.O. BOX 1358, CONCORD, NH, 03302, US	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	502	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a polymeric drug delivery system including a hydrogel containing one or more drugs for the treatment of a posterior segment disease. Allowing passive transference of this drug from a dilute solution into the hydrogel produces the delivery system. The hydrogel, when placed in contact with the eye, delivers the drug. The delivery of the drug is sustained over an extended period of time, which is of particular utility in the eye, which is periodically flushed with tears. This sustained delivery accelerates the treatment process while avoiding potential damaging effects of localized delivery of high concentrations of compounds, e.g., from eye drops.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:261978 USPATFULL  
TITLE: Anti-cancer combinations  
INVENTOR(S): Wilson, William R., Waiuku, NEW ZEALAND  
Siim, Bronwyn G., Mt. Eden, NEW ZEALAND  
PATENT ASSIGNEE(S): Cancer Research Technology Limited (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004204480	A1	20041014
APPLICATION INFO.:	US 2004-790943	A1	20040302 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2002-GB4025	20020903
	GB 2001-21285	20010903
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1297	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound

selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. Preferably, the present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from carboplatin, gemcitabine, cisplatin, 5-fluorouracil, cyclophosphamide, etoposide, vincristine, doxorubicin and irinotecan. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations. The invention further provides for methods of preparing the combinations of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:42:36 ON 13 FEB 2008)

FILE 'REGISTRY' ENTERED AT 15:42:51 ON 13 FEB 2008

E "DMXAA"/CN 25

L1 1 S E3

E "DMXAA"/CN 25

E "GEMCITABINE"/CN 25

L2 1 S E3

FILE 'CAPLUS, MEDLINE, WPIDS, USPATFULL' ENTERED AT 15:43:57 ON 13 FEB 2008

L3 7 S L1 AND L2

L4 4 S L1 AND ANTIMETABOLITE

=> d his

(FILE 'HOME' ENTERED AT 15:42:36 ON 13 FEB 2008)

FILE 'REGISTRY' ENTERED AT 15:42:51 ON 13 FEB 2008

E "DMXAA"/CN 25

L1 1 S E3

E "DMXAA"/CN 25

E "GEMCITABINE"/CN 25

L2 1 S E3

FILE 'CAPLUS, MEDLINE, WPIDS, USPATFULL' ENTERED AT 15:43:57 ON 13 FEB 2008

L3 7 S L1 AND L2

L4 4 S L1 AND ANTIMETABOLITE

=>

---Logging off of SIN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

36.21

51.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 15:46:10 ON 13 FEB 2008